Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zolpidem is a sedative-hypnotic medication used primarily for the short-term treatment of insomnia. It acts as a positive modulator of GABA~A~ receptors, specifically targeting the α1 subunit, which enhances GABAergic inhibition in the central nervous system. This results in strong hypnotic effects with minimal anxiolytic, myorelaxant, and anticonvulsant properties. Zolpidem is effective in reducing sleep onset latency and improving sleep quality but may cause serious sleep behaviors such as sleepwalking or driving while not fully awake.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zolpidem.